Introduction
Exscientia was an Oxford-area biotechnology company founded in 2012 that pioneered AI-driven precision drug design — automating molecule creation from target hypothesis through preclinical candidate nomination. Andrew Hopkins founded Exscientia as a University of Dundee spinout and built one of the first AI drug discovery companies to advance AI-designed candidates into human trials. As of November 20, 2024, Exscientia is no longer an independent public company: Recursion Pharmaceuticals completed a combination transaction and Exscientia became a wholly owned subsidiary, with Exscientia ADSs delisted from Nasdaq.
Brel profiles Exscientia as an acquired entity because hospital and pharma readers still encounter the brand in pipeline references, SEC filings, and historical partnerships — but current corporate authority sits with Recursion Pharmaceuticals.
Exscientia was incorporated in Scotland in July 2012 per its IPO filings, with global headquarters at Oxford Science Park — geographic roots Brel retains because post-acquisition Recursion lists the Oxford area among primary offices.
Company status: Acquired. Website redirects to Recursion at review.
What the company does
Exscientia’s platform applied machine learning to design drug candidates with stated goals of reducing time from target to preclinical candidate versus traditional medicinal chemistry cycles. The company operated from the Oxford Science Park and expanded to offices in Dundee, Vienna, Miami, and other locations during its independent years. Post-acquisition, Exscientia’s chemistry automation and design capabilities are integrated into Recursion’s vertically integrated TechBio platform rather than sold as a standalone vendor product.
Hopkins founded Exscientia as a University of Dundee spinout in 2012, among the earliest AI drug design companies to advance candidates into clinical testing — establishing proof points Recursion now inherits as combined pipeline assets.
Who it serves
During its independent period, Exscientia partnered with major pharmaceutical companies on AI-designed programs and licensed its platform for collaborative discovery. After November 20, 2024, external customers interact with Recursion as the parent entity. Researchers citing Exscientia publications or clinical candidates should verify current program ownership under Recursion’s pipeline disclosures.
UKRI and University of Dundee impact case studies document Exscientia’s spinout origins and clinical-pipeline milestones during its independent years — historical references Brel retains for readers tracing AI drug design genealogy without treating Exscientia as a standalone vendor today.
Company background
Hopkins founded Exscientia in 2012, growing it through venture funding and a 2021 Nasdaq listing before Recursion announced a combination agreement in August 2024. The transaction closed November 20, 2024, via a UK court-sanctioned scheme of arrangement. Recursion stated the combined company would have approximately 800 employees with headquarters remaining in Salt Lake City and primary offices including the Oxford area, Toronto, Montreal, and London.
Brel does not list David Hallett or other post-Hopkins Exscientia executives as current leadership because the entity is acquired; corporate authority resides with Recursion as of review date.
Product and AI capabilities
Exscientia’s AI stack focused on active learning for molecule design — iteratively synthesizing and testing compounds suggested by models rather than screening fixed libraries alone. This complemented Recursion’s phenotypic screening approach, which starts from cellular images and assays at scale. The combination thesis is that pairing Exscientia’s precision chemistry with Recursion’s biological data engine yields faster iteration across the discovery funnel.
Exscientia’s centaur chemistry model — combining AI suggestions with human medicinal chemist judgment — was a defining workflow during its independent years and informs how Recursion may organize hybrid human-AI teams post-acquisition. Andrew Hopkins founded the company; Brel cites Hopkins only as founder of the acquired entity.
Key developments
2012: Exscientia founded in Oxford area by Andrew Hopkins. November 20, 2024: Recursion combination completed; Exscientia wholly owned subsidiary; Nasdaq delisting. At Brel review July 2026, exscientia.com redirects to recursion.com. Combined company cited at approximately 800 employees with HQ remaining Salt Lake City. Transaction announced August 2024, closed via UK scheme of arrangement.
Why it matters
Exscientia matters historically as one of the first AI drug design companies to reach public markets — and strategically as a consolidation datapoint. Recursion’s acquisition tests whether merged AI discovery platforms outperform standalone vendors. Readers evaluating Insilico Medicine or Owkin should note Exscientia as precedent for pharma-driven M&A in the category.
Combined employee count of approximately 800 cited in Recursion’s November 2024 release gives scale context for post-merger integration — a factor pipeline analysts watch when assessing whether chemistry automation and phenotypic screening actually merge operationally.
Brel does not list David Hallett as current CEO; acquired entity governed by Recursion.
Sector context
Exscientia belongs in Brel’s AI in healthcare coverage under acquired AI drug discovery assets, now part of Recursion Pharmaceuticals. Active peers include Insilico Medicine and Owkin.
Readers researching Exscientia pipeline assets should consult Recursion investor materials for current program status — Brel treats November 20, 2024 as the independence end date for corporate governance and executive authority purposes.
Acquired November 20, 2024. Reviewed 2026-07-10.
Sources and references
Recursion combination press release (November 20, 2024) and Exscientia about page where accessible.
- Recursion — Exscientia combination (ir.recursion.com, November 20, 2024)
- Exscientia — About Us (exscientia.com)
Reviewed July 10, 2026. Company status Acquired. Andrew Hopkins is founder. exscientia.com redirects to recursion.com at review. Confidence High. Oxford UK origin city.